-
公开(公告)号：US20170304271A1
公开(公告)日：2017-10-26
申请号：US15497307
申请日：2017-04-26
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Ruichao Shen , Xuechao Xing , Brett Granger , Bin Wang , Jun Ma , Jing He , Yong He , Jiang Long , Guoqiang Wang
IPC: A61K31/42 , C07D277/62 , C07D275/04 , C07D261/08 , A61K31/64 , A61K31/545 , A61K31/4725 , C07D413/12 , A61K31/426
CPC classification number: A61K31/42 , A61K31/426 , A61K31/4725 , A61K31/545 , A61K31/64 , C07D261/08 , C07D275/04 , C07D277/62 , C07D413/12 , C07D413/14 , C07D417/14
Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
公开(公告)号：US20170240585A1
公开(公告)日：2017-08-24
申请号：US15439358
申请日：2017-02-22
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Yat Sun Or , Jiang Long , Guoyou Xu , Peng Dai , Ruichao Shen , Xuechao Xing , Jing He
CPC classification number: C07J41/0055 , C07B59/007 , C07B2200/05 , C07J9/005 , C07J17/00 , C07J43/003 , C07J51/00
Abstract: The present invention provides compounds of Formula (I) or Formula (II): pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.
-
公开(公告)号：US12018017B2
公开(公告)日：2024-06-25
申请号：US18073728
申请日：2022-12-02
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Ruichao Shen , Jiang Long , Jun Ma , Xuechao Xing , Yong He , Brett Granger , Jing He , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14
CPC classification number: C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof:
which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).-
74.发明公开公开(公告)号：US20240132476A1
公开(公告)日：2024-04-25
申请号：US18383949
申请日：2023-10-25
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Ruichao Shen , Brett Granger , Jing He , Xuechao Xing , Yong He , Jiang Long , Jun Ma , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
CPC classification number: C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:
which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).-
公开(公告)号：US11958879B2
公开(公告)日：2024-04-16
申请号：US17324464
申请日：2021-05-19
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Xuechao Xing , Jiang Long , Peng Dai , Brett Granger , Jing He
CPC classification number: C07J43/003 , C07J41/005 , C07J41/0055 , C07J41/0088 , C07J9/00 , C07J9/005 , C07J51/00
Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof,
The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.-
Patent Agency Ranking
公开(公告)号：US11945824B2
公开(公告)日：2024-04-02
申请号：US17503626
申请日：2021-10-18
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Yat Sun Or , Yong He , Kevin McGrath , Ruichao Shen , Adam Szymaniak , Xuechao Xing , In Jong Kim , Guoqiang Wang
IPC: A61K31/706 , A61K31/635 , A61K45/06 , A61P31/14 , A61P35/00 , C07D491/048
CPC classification number: C07D491/048 , A61K45/06 , A61P31/14
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.-
公开(公告)号：US11718641B2
公开(公告)日：2023-08-08
申请号：US17186447
申请日：2021-02-26
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Jiang Long , Peng Dai , Xuechao Xing , Jing He
CPC classification number: C07J41/0066 , C07J41/0055 , C07J41/0088 , C07J43/003 , C07J43/006 , C07J9/005 , C07J41/0094 , C07J51/00
Abstract: The present invention provides compounds of Formula I,
pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.-
公开(公告)号：US20230203048A1
公开(公告)日：2023-06-29
申请号：US17983474
申请日：2022-11-09
Applicant: ENANTA PHARMACEUTICALS, INC
Inventor： Guoqiang Wang , Ruichao Shen , Xuechao Xing , Yong He , Matthew C. Rhodes , Yat Sun Or
IPC: C07D487/10 , A61P31/14
CPC classification number: C07D487/10 , A61P31/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:
which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.-
公开(公告)号：US11560368B2
公开(公告)日：2023-01-24
申请号：US17197399
申请日：2021-03-10
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Ruichao Shen , Jiang Long , Jun Ma , Xuechao Xing , Yong He , Brett Granger , Jing He , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D405/14 , C07D403/14 , C07D413/14 , C07D417/14 , C07D403/12
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
公开(公告)号：US20220402966A1
公开(公告)日：2022-12-22
申请号：US17324464
申请日：2021-05-19
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Xuechao Xing , Jiang Long , Peng Dai , Brett Granger , Jing He
Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
-
-
-
-
-
-
-
-
-
Search Results
93
records
(took 0.023 seconds)
